Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory …

X Zhou, V Wagner, L Scheller… - British Journal of … - Wiley Online Library
Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR)
multiple myeloma (MM) are not completely defined. We prospectively analysed 275 …
被引用次数：1 相关文章

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory …

X Zhou, V Wagner, L Scheller… - British journal of … - pubmed.ncbi.nlm.nih.gov
Biomarkers for cytopenias following CAR T-cell treatment in relapsed/refractory (RR)
multiple myeloma (MM) are not completely defined. We prospectively analysed 275 …

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory …

X Zhou, V Wagner, L Scheller… - British Journal of …, 2024 - europepmc.org
Biomarkers for cytopenias following CAR T-cell treatment in relapsed/refractory (RR)
multiple myeloma (MM) are not completely defined. We prospectively analysed 275 …